

## Disclosures

### Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
cardiol therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Pericardial Disease
Elsevier	Consultant Fees/Honoraria	Modest (< \$5,000)	Noninvasive Imaging
Kiniksa	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pericardial Disease
Kiniksa	Research/Research Grants ‡ Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis	None (\$0)	Pericardial Disease
ventyx	Consultant Fees/Honoraria	Modest (< \$5,000)	Other
ventyx	Research/Research Grants ‡ A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis	None (\$0)	Pericardial Disease
Wolters Kluwer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Noninvasive Imaging
Zydus Pharmaceuticals	Consultant Fees/Honoraria	None (\$0)	Pericardial Disease

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Pericarditis Alliance ‡ none	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	Pericardial Disease

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

‡ Commercial Funding Source | ‡ Trial Name

## Agreement

**Certified Education Attestation** | Signed on 12/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 12/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

**Embargo** | Signed on 12/10/2025

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

**On-Going Obligation Agreement** | Signed on 2/11/2026

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.